# EDGAR Filing Document

**Accession Number:** 0001178670
**File Stem:** 0001193125-23-046503
**Filing Date:** 2023-2
**Character Count:** 14121
**Document Hash:** 80f42163076181f34945c138e564254e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-046503.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0001193125-23-046503

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230223

**DATE AS OF CHANGE**: 20230223

**EFFECTIVENESS DATE**: 20230223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALNYLAM PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001178670
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770602661
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269939
- **FILM NUMBER:** 23659533

**BUSINESS ADDRESS:**
- **STREET 1:** 675 WEST KENDALL STREET
- **STREET 2:** HENRI A. TERMEER SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** (617) 551-8200

**MAIL ADDRESS:**
- **STREET 1:** 675 WEST KENDALL STREET
- **STREET 2:** HENRI A. TERMEER SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALNYLAM PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020724

**As filed with the Securities and Exchange Commission on February 23, 2023** 

**Registration No. 333-<u> </u>** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## Alnylam Pharmaceuticals, Inc.
**(Exact Name of Registrant as Specified in Its Charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **77-0602661** |
| **(State or Other Jurisdiction of**<br> **Incorporation or Organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **675 West Kendall Street,**<br> **Henri A. Termeer Square**<br> **Cambridge, Massachusetts 02142** | **02142** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Amended and Restated 2018 Stock Incentive Plan** 

**(Full Title of the Plans)** 

**Yvonne Greenstreet, MBChB** 

**Chief Executive Officer** 

**Alnylam Pharmaceuticals, Inc.** 

**675 West Kendall Street,** 

**Henri A. Termeer Square** 

**Cambridge, Massachusetts 02142** 

**(Name and Address of Agent For Service)** 

**(617) 551-8200** 

**(Telephone Number, Including Area Code, of Agent For Service)** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ (Do not check if a smaller reporting company) | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

On March 31, 2022, the board of directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the "Registrant") approved an amendment and restatement of the Registrant's 2018 Stock Incentive Plan, as amended (the "2018 Plan", and as amended and restated, the "Amended Plan"), pursuant to which the number of shares of common stock, par value $0.01 per share ("Common Stock") reserved and available for issuance under the 2018 Plan increased by 6,000,000 shares subject to stockholder approval, which was received on May 18, 2022. This Registration Statement on Form S-8 registers these 6,000,000 additional shares of Common Stock. The additional shares available for issuance under the Amended Plan are of the same class as other securities relating to the 2018 Plan for which the Registrant's registration statements filed on Form S-8 (Registration No. 333-226533) on [August 2, 2018](http://www.sec.gov/Archives/edgar/data/1178670/000119312518236768/d591157ds8.htm), on Form S-8 (Registration No. 333-236409) on [February 13, 2020](http://www.sec.gov/Archives/edgar/data/1178670/000119312520034390/d868105ds8.htm), and on Form S-8 (Registration No. 333-252994) on [February 11, 2021](http://www.sec.gov/Archives/edgar/data/1178670/000119312521038563/d114010ds8.htm), are effective.

The information contained in the Registrant's prior registration statements on Form S-8 referenced above is hereby incorporated by reference pursuant to General Instruction E, except for "Item 8. Exhibits."

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 8. <u>Exhibits</u>.** 

---

| | |
|:---|:---|
| **Number** | **Description** |
| 5.1\* | [Opinion of Goodwin Procter LLP, counsel to the Registrant.](d460009dex51.htm) |
| 23.1\* | [Consent of Goodwin Procter LLP (included in Exhibit 5.1).](d460009dex51.htm) |
| 23.2\* | [Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.](d460009dex232.htm) |
| 24.1\* | [Power of Attorney (included on the signature page of this registration statement).](d460009ds8.htm#sig) |
| 99.1 | [Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q filed on July 28, 2022 (File No. 001-36407) for the quarterly period ended June 30, 2022).](http://www.sec.gov/Archives/edgar/data/1178670/000117867022000020/alny2022q210-qex101.htm) |
| 107.1\* | [Filing Fee Table.](d460009dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 23rd day of February, 2023.

---

| | |
|:---|:---|
|  ALNYLAM PHARMACEUTICALS, INC. | ALNYLAM PHARMACEUTICALS, INC. |
|  By: | /s/ Yvonne L. Greenstreet, MBChB |
|  | Yvonne L. Greenstreet, MBChB |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES** 

We, the undersigned officers and directors of Alnylam Pharmaceuticals, Inc., hereby severally constitute and appoint Yvonne L. Greenstreet MBChB and Jeffrey V. Poulton, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Alnylam Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Yvonne L. Greenstreet, MBChB<br> Yvonne L. Greenstreet, MBChB | Chief Executive Officer and Director<br> (Principal Executive Officer) | February 23, 2023 |
| /s/ Jeffrey V. Poulton<br> Jeffrey V. Poulton | Executive Vice President and Chief Financial Officer<br> (Principal Financial and Accounting Officer) | February 23, 2023 |
| /s/ Dennis A. Ausiello, M.D.<br> Dennis A. Ausiello, M.D. | Director | February 23, 2023 |
| /s/ Carolyn R. Bertozzi, Ph.D.<br> Carolyn R. Bertozzi, Ph.D. | Director | February 23, 2023 |
| /s/ Michael W. Bonney<br> Michael W. Bonney | Director | February 23, 2023 |
| /s/ Olivier Brandicourt, M.D.<br> Olivier Brandicourt, M.D. | Director | February 23, 2023 |
| /s/ Marsha H. Fanucci<br> Marsha H. Fanucci | Director | February 23, 2023 |
| /s/ Margaret A. Hamburg, M.D.<br> Margaret A. Hamburg, M.D. | Director | February 23, 2023 |
| /s/ David E.I. Pyott<br> David E.I. Pyott | Director | February 23, 2023 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Colleen F. Reitan<br> Colleen F. Reitan | Director | February 23, 2023 |
| /s/ Amy W. Schulman<br> Amy W. Schulman | Director | February 23, 2023 |
| /s/ Phillip A. Sharp, Ph.D.<br> Phillip A. Sharp, Ph.D. | Director | February 23, 2023 |
| /s/ Elliott Sigal, M.D., Ph.D.<br> Elliott Sigal, M.D., Ph.D. | Director | February 23, 2023 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g460009g01a01.jpg) | Goodwin Procter LLP<br> 100 Northern Avenue<br> Boston, MA 02210<br> goodwinlaw.com<br> +1 617 570 1000 |

---

<br>February 23, 2023

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street

Henri A. Termeer Square

Cambridge, Massachusetts 02142

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 6,000,000 shares (the "Shares") of Common Stock, $0.01 par value per share ("Common Stock"), of Alnylam Pharmaceuticals, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's Amended and Restated 2018 Stock Incentive Plan (the "Plan").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Goodwin Procter LLP

GOODWIN PROCTER LLP

## Exhibit 23.2

**Exhibit 23.2** 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Alnylam Pharmaceuticals, Inc. of our report dated February 23, 2023 relating to the financial statements, and the effectiveness of internal control over financial reporting, which appears in Alnylam Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2022.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

February 23, 2023

## Ex-Filing

**Exhibit 107.1** 

**Table 1. Newly Registered Securities** 

**CALCULATION OF REGISTRATION FEE** 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;Security Type | Security<br>Class<br> Title | Fee<br>Calculation<br>Rule | Amount<br> Registered(1) | Proposed<br> Maximum<br> Offering<br>Price per<br>Share(2) | Maximum<br> Aggregate<br> Offering<br> Price | Fee<br> Rate | Amount of<br> Registration<br> Fee |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock, $0.01<br> par value per share | Other(2) | 6,000,000 shares(3) | $201.42 | $1208520000.00 | $0.0001102 | $133179.00 |
| &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts |  | $1208520000.00 |  | $133179.00 |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets |  |  |  | $0 |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  |  | $133179.00 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock which become issuable under the Registrant's Amended and Restated 2018 Stock Incentive Plan (the "Amended Plan") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock.

(2) Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $201.42 per share, which is the average of the high and low prices of the common stock on February 22, 2023, as reported on the Nasdaq Global Select Market.

(3) Represents 6,000,000 shares of common stock that were added to the shares authorized for issuance under the Amended Plan, pursuant to the approval of the Amended Plan approved by the Registrant's board of directors (the "Board") on March 31, 2022 and its stockholders on May 18, 2022.